# Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

> **NCT00066573** · PHASE3 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 7576 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** anastrozole
- **DRUG:** exemestane

## Key facts

- **NCT ID:** NCT00066573
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06-06
- **Primary completion:** 2010-11-07
- **Final completion:** 2012-01-06
- **Target enrollment:** 7576 (ACTUAL)
- **Last updated:** 2023-08-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00066573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00066573, "Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00066573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*